Improvement of renal function after transcatheter aortic valve replacement and its impact on survival.
Cardiorenal syndrome
Renal function
Renal improvement
TAVR
Journal
BMC nephrology
ISSN: 1471-2369
Titre abrégé: BMC Nephrol
Pays: England
ID NLM: 100967793
Informations de publication
Date de publication:
02 03 2021
02 03 2021
Historique:
received:
13
08
2020
accepted:
18
02
2021
entrez:
3
3
2021
pubmed:
4
3
2021
medline:
15
12
2021
Statut:
epublish
Résumé
Chronic kidney disease as well as acute kidney injury are associated with adverse outcomes after transcatheter aortic valve replacement (TAVR). However, little is known about the prognostic implications of an improvement in renal function after TAVR. Renal improvement (RI) was defined as a decrease in postprocedural creatinine in μmol/l of ≥1% compared to its preprocedural baseline value. A propensity score representing the likelihood of RI was calculated to define patient groups which were comparable regarding potential confounders (age, sex, BMI, NYHA classification, STS score, log. EuroSCORE, history of atrial fibrillation/atrial flutter, pulmonary disease, previous stroke, CRP, creatinine, hsTNT and NT-proBNP). The cohort was stratified into 5 quintiles according to this propensity score and the survival time after TAVR was compared within each subgroup. Patients in quintile 5 (n = 93) had the highest likelihood for RI. They were characterized by higher creatinine, lower eGFR, higher NYHA class, higher NT-proBNP, being mostly female and having shorter overall survival time. Within quintile 5, patients without RI had significantly shorter survival compared to patients with RI (p = 0.002, HR = 0.32, 95% CI = [0.15-0.69]). There was no survival time difference between patients with and without RI in the whole cohort (p = 0.12) and in quintiles 1 to 4 (all p > 0.16). Analyses of specific subgroups showed that among patients with NYHA class IV, those with RI also had a significant survival time benefit (p < 0.001, HR = 0.15; 95%-CI = [0.05-0.44]) compared to patients without RI. We here describe a propensity score-derived specific subgroup of patients in which RI after TAVR correlated with a significant survival benefit.
Sections du résumé
BACKGROUND
Chronic kidney disease as well as acute kidney injury are associated with adverse outcomes after transcatheter aortic valve replacement (TAVR). However, little is known about the prognostic implications of an improvement in renal function after TAVR.
METHODS
Renal improvement (RI) was defined as a decrease in postprocedural creatinine in μmol/l of ≥1% compared to its preprocedural baseline value. A propensity score representing the likelihood of RI was calculated to define patient groups which were comparable regarding potential confounders (age, sex, BMI, NYHA classification, STS score, log. EuroSCORE, history of atrial fibrillation/atrial flutter, pulmonary disease, previous stroke, CRP, creatinine, hsTNT and NT-proBNP). The cohort was stratified into 5 quintiles according to this propensity score and the survival time after TAVR was compared within each subgroup.
RESULTS
Patients in quintile 5 (n = 93) had the highest likelihood for RI. They were characterized by higher creatinine, lower eGFR, higher NYHA class, higher NT-proBNP, being mostly female and having shorter overall survival time. Within quintile 5, patients without RI had significantly shorter survival compared to patients with RI (p = 0.002, HR = 0.32, 95% CI = [0.15-0.69]). There was no survival time difference between patients with and without RI in the whole cohort (p = 0.12) and in quintiles 1 to 4 (all p > 0.16). Analyses of specific subgroups showed that among patients with NYHA class IV, those with RI also had a significant survival time benefit (p < 0.001, HR = 0.15; 95%-CI = [0.05-0.44]) compared to patients without RI.
CONCLUSIONS
We here describe a propensity score-derived specific subgroup of patients in which RI after TAVR correlated with a significant survival benefit.
Identifiants
pubmed: 33653283
doi: 10.1186/s12882-021-02274-5
pii: 10.1186/s12882-021-02274-5
pmc: PMC7923662
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
77Références
Ann Thorac Surg. 2009 Jul;88(1 Suppl):S2-22
pubmed: 19559822
Cardiovasc Interv Ther. 2019 Jul;34(3):216-225
pubmed: 30232711
J Am Soc Nephrol. 2006 Jul;17(7):2034-47
pubmed: 16738019
JACC Heart Fail. 2019 Jan;7(1):25-32
pubmed: 30606484
Med Sci Monit. 2015 Apr 17;21:1089-96
pubmed: 25881555
Ann Thorac Surg. 2006 Dec;82(6):2111-5
pubmed: 17126120
BMC Cardiovasc Disord. 2018 Mar 20;18(1):55
pubmed: 29558902
Front Cardiovasc Med. 2018 Mar 28;5:31
pubmed: 29644220
Eur Heart J. 2003 May;24(9):881-2
pubmed: 12727160
Am Heart J. 2010 Feb;159(2):323-9
pubmed: 20152233
Eur J Cardiothorac Surg. 2012 Apr;41(4):734-44; discussion 744-5
pubmed: 22378855
Eur Heart J. 2010 Apr;31(7):865-74
pubmed: 20037180
Int J Cardiol. 2015 Jan 15;178:275-81
pubmed: 25464269
Circ Cardiovasc Qual Outcomes. 2009 Nov;2(6):533-9
pubmed: 20031890
Kidney Blood Press Res. 2018;43(5):1437-1450
pubmed: 30235455
Clin Cardiol. 2018 Aug;41(8):1091-1096
pubmed: 29896847
Nephrol Dial Transplant. 2020 Mar 1;35(3):433-438
pubmed: 30169857
Eur Heart J. 2003 Jul;24(13):1231-43
pubmed: 12831818
Eur J Heart Fail. 2018 May;20(5):853-872
pubmed: 29520964
JACC Cardiovasc Interv. 2010 Nov;3(11):1141-9
pubmed: 21087750
Nephron Clin Pract. 2014;127(1-4):106-12
pubmed: 25343831
Lancet. 2006 Sep 16;368(9540):1005-11
pubmed: 16980116